Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

MOUNTAIN VIEW, Calif., May 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for its fiscal quarter ended March 31, 2008 and provided an update on the Company's progress with its product candidates. The net loss for the 2008 first fiscal quarter, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $14.6 million, compared to a net loss of $10.9 million in the comparable period in 2007. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at March 31, 2008 of $111.7 million.

"The first four months of 2008 have been very productive for Alexza, as we have continued to make progress on all of our product candidates. Importantly, we initiated our first pivotal Phase 3 trial with AZ-004 (Staccato(R) loxapine)," said Thomas B King, President and CEO of Alexza. "We have a comprehensive plan in place to collect the data and other supporting information we will need to submit an NDA for AZ-004. We plan to initiate our second AZ-004 Phase 3 clinical trial in the third quarter of 2008."

Financial Results -- Three Months Ended March 31, 2008 and 2007

GAAP operating expenses were $19.2 million in the first quarter of 2008, compared to $13.8 million for the comparable period in 2007. The first quarter increase resulted from increased spending on AZ-004 and AZ-104 as the Company continued development of these product candidates under the Symphony Allegro agreement, increased spending on AZ-003 with continued development of this product candidate under the development agreement with Endo Pharmaceuticals, increased spending for device development and manufacturi
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Colo. , Jan. 23, 2015  Array BioPharma Inc. ... has reached a definitive agreement with Novartis Pharma AG ... inhibitor currently in Phase 3 development.  This agreement is conditional ... GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected ...
(Date:1/22/2015)... 22, 2015 Eckert & Ziegler Vitalea ... (AMS) services to the pharmaceutical and biotech industry, has ... company in the position of Director of Science & ... and valuable experience in drug metabolism and bioanalysis to ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... DALLAS, February 1, 2012 The report ... -   Global Trends, Opportunities & Forecasts (2011   - ... and studies the major market drivers, restraints, and opportunities in ... Browse market data tables and in-depth TOC ...
... 2012 New Report Added in ... Global Markets The report provides ... DDS and future opportunities (2011-2021).  Persons with a financial ... to learn how advances in nanotechnology research and development ...
... in Dayton, Ohio, has experimentally confirmed a theory by ... of interesting properties about nanotube growth: That the chirality ... and that armchair nanotubes should grow the fastest. ... the mysteries inherent in what Yakobson calls the "DNA ...
Cached Biology Technology:MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 2MarketsandMarkets: Global Biomarkers Market worth $25.79 Billion by 2016 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 2ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 3ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets 4Rice professor's nanotube theory confirmed 2Rice professor's nanotube theory confirmed 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
... (11/12/2012) If you,ve eaten fish, gone for a boat ride or ... is a valuable commodity. But just how valuable? That,s always been ... the worth of clean water against societal needs that compromise it, ... Now, however, their ability to do so has been greatly enhanced ...
... have estimated that there are 1.7 million species of ... continue to be discovered. Unfortunately, as new species are ... decrease in biodiversity. The more diversity there is in ... Hence, biodiversity is key to ecosystem resilience. Disease, ...
Cached Biology News:Plan to turn farm waste into paper earns students $15,000 2Study offers new tool for incorporating water impacts into policy decisions 2Persistence or extinction: Through a mathematical lens 2Persistence or extinction: Through a mathematical lens 3